Do PD-L1 expression levels influence non-small cell lung cancer patients’ outcomes? Special guest Jason Porter, MD., discusses how PD-L1 levels affected treatment outcomes in a clinical study for recurrent or metastatic non-small cell lung canc

Dr. Jason Porter on Neoadjuvant Treatment for Resectable NSCLC

Apr 19th, 2023 33m 30s

In the early stages of non-small cell lung cancer, is curative surgery or perioperative systemic therapy the right approach? Although every patient is different, there may be various ways to individually approach resectable non-small cell lung

Dr. Shilpa Gupta, MD, on an Adjuvant I-O Therapy in UC

Apr 19th, 2023 44m 6s

There is ongoing progress in the urothelial carcinoma treatment landscape, but after radical resection, what adjuvant options are there for your patient? Special guest Shilpa Gupta, MD, joins us to discuss the various ways to individually appro

Rate